secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004109
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam reports preliminary FY2022 net product revenue of $894M, up 35% YoY
---------------------------------------------------------------------------

- ONPATTRO: Q4 $122M, FY $558M; AMVUTTRA: Q4 $69M, FY $94M; combined TTR revenue grew 37% YoY.
- GIVLAARI: Q4 $47M, FY $173M (+35% YoY); OXLUMO: Q4 $24M, FY $70M (+17% YoY).
- Year-end cash and marketable securities ~$2.2B, down from $2.4B at end 2021.
- Over 2,975 patients on commercial TTR drugs and over 520 on GIVLAARI; 280 on OXLUMO as of year-end.
- Management cites strong AMVUTTRA launch and reiterates Alnylam P5x25 strategic goals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/0001193125-23-004109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer